Cargando…

Paricalcitol reduces oxidative stress and inflammation in hemodialysis patients

BACKGROUND: Treatment with selective vitamin D receptor activators such as paricalcitol have been shown to exert an anti-inflammatory effect in patients on hemodialysis, in addition to their action on mineral metabolism and independently of parathyroid hormone (PTH) levels. The objective of this stu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Izquierdo, María Jesús, Cavia, Mónica, Muñiz, Pilar, de Francisco, Angel LM, Arias, Manuel, Santos, Javier, Abaigar, Pedro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3520723/ https://www.ncbi.nlm.nih.gov/pubmed/23186077 http://dx.doi.org/10.1186/1471-2369-13-159

Ejemplares similares

Mortality in Hemodialysis Patients with COVID-19, the Effect of Paricalcitol or Calcimimetics
por: Arenas Jimenez, María Dolores, et al.
Publicado: (2021)

Asymmetric Dimethylarginine (ADMA) Levels Are Lower in Hemodialysis Patients Treated With Paricalcitol
por: Oliva-Damaso, Elena, et al.
Publicado: (2016)

Paricalcitol in hemodialysis patients with secondary hyperparathyroidism and its potential benefits
por: Chen, Xiu, et al.
Publicado: (2021)

Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis
por: Liu, Yang, et al.
Publicado: (2019)

Etelcalcetide and Paricalcitol in Chronic Kidney Disease: When the Target Is Inflammation
por: D’Marco, Luis, et al.
Publicado: (2022)

Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients
por: Cruzado, Josep M., et al.
Publicado: (2017)

Cholecalciferol Additively Reduces Serum Parathyroid Hormone and Increases Vitamin D and Cathelicidin Levels in Paricalcitol-Treated Secondary Hyperparathyroid Hemodialysis Patients
por: Zheng, Jing-Quan, et al.
Publicado: (2016)

Exploring the potential effect of paricalcitol on markers of inflammation in de novo renal transplant recipients
por: Pihlstrøm, Hege Kampen, et al.
Publicado: (2020)

Biomarkers of Oxidative Stress in Healthy Infants within the First Three Days after Birth
por: Cavia-Saiz, Mónica, et al.
Publicado: (2023)

Paricalcitol Ameliorates Acute Kidney Injury in Mice by Suppressing Oxidative Stress and Inflammation via Nrf2/HO-1 Signaling
por: Wang, Shuang, et al.
Publicado: (2023)

Paricalcitol Reduces Peritoneal Fibrosis in Mice through the Activation of Regulatory T Cells and Reduction in IL-17 Production
por: González-Mateo, Guadalupe T., et al.
Publicado: (2014)

Paricalcitol attenuates lipopolysaccharide-induced myocardial inflammation by regulating the NF-κB signaling pathway
por: LEE, AE SIN, et al.
Publicado: (2016)

Antiapoptotic Effect of Paricalcitol in Gentamicin-induced Kidney Injury
por: Suh, Sang Heon, et al.
Publicado: (2013)

Oral Paricalcitol for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease
por: Cheng, Steven, et al.
Publicado: (2006)

Protective Effects of Paricalcitol on Peritoneal Remodeling during Peritoneal Dialysis
por: Stavenuiter, Andrea W. D., et al.
Publicado: (2015)

Role of Paricalcitol in Modulating the Immune Response in Patients with Renal Disease
por: Lucisano, Silvia, et al.
Publicado: (2015)

Effects of Paricalcitol on Body Composition in Vitamin D-Deficient Rats
por: Koohpeyma, Farhad, et al.
Publicado: (2021)

Beneficial Effects of Olive Oil Enriched with Lycopene on the Plasma Antioxidant and Anti-Inflammatory Profile of Hypercholesterolemic Patients
por: Martínez Álvarez, Jesus Roman, et al.
Publicado: (2023)

Effects of Hypothermia and Allopurinol on Oxidative Status in a Rat Model of Hypoxic Ischemic Encephalopathy
por: Durán Fernández-Feijóo, Cristina, et al.
Publicado: (2021)

Comparison of the Pharmacological Effects of Paricalcitol and Doxercalciferol on the Factors Involved in Mineral Homeostasis
por: Wu-Wong, J. Ruth, et al.
Publicado: (2010)

Cardiac and Renal Effects of Atrasentan in Combination with Enalapril and Paricalcitol in Uremic Rats
por: Ritter, Cynthia, et al.
Publicado: (2014)

Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients
por: de Francisco, Angel L.M., et al.
Publicado: (2017)

Paricalcitol attenuates lipopolysaccharide-induced inflammation and apoptosis in proximal tubular cells through the prostaglandin E(2) receptor EP4
por: Hong, Yu Ah, et al.
Publicado: (2017)

Bioaccessibility and Genoprotective Effect of Melanoidins Obtained from Common and Soft Bread Crusts: Relationship between Melanoidins and Their Bioactivity
por: Temiño, Virginia, et al.
Publicado: (2023)

The Effect of Paricalcitol on Vascular Calcification and Cardiovascular Disease in Uremia: Beyond PTH Control
por: Cozzolino, Mario, et al.
Publicado: (2011)

Differential expression and regulation of Klotho by paricalcitol in the kidney, parathyroid and aorta of uremic rats
por: Ritter, Cynthia S., et al.
Publicado: (2015)

Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease
por: Webb, Nicholas J. A., et al.
Publicado: (2017)

Neuroprotective effect of paricalcitol in a rat model of transient global cerebral ischemia
por: Kim, Sung Wook, et al.
Publicado: (2020)

Paricalcitol Attenuates Contrast-Induced Acute Kidney Injury by Regulating Mitophagy and Senescence
por: Bae, Eunjin, et al.
Publicado: (2020)

Preclinical Therapy with Vitamin D3 in Experimental Encephalomyelitis: Efficacy and Comparison with Paricalcitol
por: Mimura, Luiza Ayumi Nishiyama, et al.
Publicado: (2021)

Paricalcitol Attenuates 4-Hydroxy-2-Hexenal-Induced Inflammation and Epithelial-Mesenchymal Transition in Human Renal Proximal Tubular Epithelial Cells
por: Kim, Chang Seong, et al.
Publicado: (2013)

The influence of selective vitamin D receptor activator paricalcitol on cardiovascular system and cardiorenal protection
por: Duplancic, Darko, et al.
Publicado: (2013)

Successful Treatment of Severe Atopic Dermatitis with Calcitriol and Paricalcitol in an 8-Year-Old Girl
por: Bothou, Christina, et al.
Publicado: (2018)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Paricalcitol Improves Hypoxia-Induced and TGF-β1-Induced Injury in Kidney Pericytes
por: Lim, Jeong-Hoon, et al.
Publicado: (2021)

Paricalcitol Attenuates Metabolic Syndrome-Associated Heart Failure through Enhanced Mitochondrial Fusion
por: Nizami, Hina L., et al.
Publicado: (2022)

Paricalcitol Improves the Angiopoietin/Tie-2 and VEGF/VEGFR2 Signaling Pathways in Adriamycin-Induced Nephropathy
por: Deluque, Amanda Lima, et al.
Publicado: (2022)

TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status
por: Herreros-Villanueva, Marta, et al.
Publicado: (2010)

Correction: Paricalcitol Attenuates 4-Hydroxy-2-Hexenal-Induced Inflammation and Epithelial-Mesenchymal Transition in Human Renal Proximal Tubular Epithelial Cells
por: Kim, Chang Seong, et al.
Publicado: (2013)

Treatment of secondary hyperparathyroidism in haemodialysis patients: a randomised clinical trial comparing paricalcitol and alfacalcidol
por: Hansen, Ditte, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_1l3vc7gn1m62ljomuv2qgo2n3m